BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer

Reuters

03/16

** Shares of biotech firm Monte Rosa Therapeutics GLUE.O rise 5.1% to $16.85 premarket

** Co says it will start a mid‑stage study of its experimental prostate cancer drug MRT‑2359 with Johnson & Johnson’s JNJ.N Erleada

** Trial will test the combo in men with advanced prostate cancer that no longer responds to hormone therapy, a hard‑to‑treat stage of the disease - GLUE

** MRT‑2359 is an oral experimental drug designed to break down a protein that helps cancer cells survive, co says

** Study expected to begin in the third quarter of 2026 and enroll up to 25 patients, with Monte Rosa running the trial and J&J supplying Erleada - GLUE

** Erleada is already approved for certain prostate cancers; study will track PSA levels, tumor size and disease progression, co says

** Shares up about two fold in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2619452077"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619452077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619452077?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619452077","market":"us","top_or_hot":-1,"title":"BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer</title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> <span>GLUE.O</span> rise 5.1% to $16.85 premarket</p><p>** Co says it will start a mid‑stage study of its experimental prostate cancer drug MRT‑2359 with Johnson &amp; Johnson’s <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span> Erleada</p><p>** Trial will test the combo in men with advanced prostate cancer that no longer responds to hormone therapy, a hard‑to‑treat stage of the disease - GLUE</p><p>** MRT‑2359 is an oral experimental drug designed to break down a protein that helps cancer cells survive, co says</p><p>** Study expected to begin in the third quarter of 2026 and enroll up to 25 patients, with Monte Rosa running the trial and J&amp;J supplying Erleada - GLUE</p><p>** Erleada is already approved for certain prostate cancers; study will track PSA levels, tumor size and disease progression, co says</p><p>** Shares up about two fold in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-16 19:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer</title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> <span>GLUE.O</span> rise 5.1% to $16.85 premarket</p><p>** Co says it will start a mid‑stage study of its experimental prostate cancer drug MRT‑2359 with Johnson &amp; Johnson’s <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span> Erleada</p><p>** Trial will test the combo in men with advanced prostate cancer that no longer responds to hormone therapy, a hard‑to‑treat stage of the disease - GLUE</p><p>** MRT‑2359 is an oral experimental drug designed to break down a protein that helps cancer cells survive, co says</p><p>** Study expected to begin in the third quarter of 2026 and enroll up to 25 patients, with Monte Rosa running the trial and J&amp;J supplying Erleada - GLUE</p><p>** Erleada is already approved for certain prostate cancers; study will track PSA levels, tumor size and disease progression, co says</p><p>** Shares up about two fold in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2129689514.USD","symbol_name":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL4N4040WW:1","article_id":"2619452077","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619452077","pubTimestamp":1773659458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer** Shares of biotech firm Monte Rosa Therapeutics GLUE.O rise 5.1% to $16.85 premarket** Co says it will start a midstage study of its experimental prostate cancer drug MRT2359 with Johnson & Johnson’s JNJ.N Erleada** Trial will test the combo in men with advanced prostate cancer that no longer responds to hormone therapy, a hardtotreat stage of the disease - GLUE** MRT2359 is an oral experimental drug designed to break down a protein that helps cancer cells survive, co says** Study expected to begin in the third quarter of 2026 and enroll up to 25 patients, with Monte Rosa running the trial and J&J supplying Erleada - GLUE** Erleada is already approved for certain prostate cancers; study will track PSA levels, tumor size and disease progression, co says** Shares up about two fold in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0058720904.USD":"联博国际健康护理基金A","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","BK4559":"巴菲特持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4588":"碎股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","GLUE":"Monte Rosa Therapeutics","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","JNJ":"强生","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4139":"生物科技","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC"},"translate_title":"BUZZ-Monte Rosa因在晚期前列腺癌中进行新的组合试验而引起关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":0.9,"JNJ":0.9},"content_text":"BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer** Shares of biotech firm Monte Rosa Therapeutics GLUE.O rise 5.1% to $16.85 premarket** Co says it will start a mid‑stage study of its experimental prostate cancer drug MRT‑2359 with Johnson & Johnson’s JNJ.N Erleada** Trial will test the combo in men with advanced prostate cancer that no longer responds to hormone therapy, a hard‑to‑treat stage of the disease - GLUE** MRT‑2359 is an oral experimental drug designed to break down a protein that helps cancer cells survive, co says** Study expected to begin in the third quarter of 2026 and enroll up to 25 patients, with Monte Rosa running the trial and J&J supplying Erleada - GLUE** Erleada is already approved for certain prostate cancers; study will track PSA levels, tumor size and disease progression, co says** Shares up about two fold in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}